Mathews Journal of Surgery

2575-9531
Network
  • likes
  • Followers
  • Subscribers
  • Latest Tweets
    Facebook Likes

    Previous Issues Volume 1, Issue 2 - 2017

    Editorial ArticlePDF  

    Terlipressin Abuse:An Occult Killer for Patients with Critical Condition

    Gong Jian-Hua*, Zhou Yu, Kong Siya

    Hangzhou First People’s Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, China.

    Corresponding Author: Gong Jian-Hua, Hangzhou First People’s Hospital, Nanjing Medical University Affiliated Hospital, China, Tel: +86 25 8686 2618; Email: jiazhong20058@hotmail.com

    Received Date: 07 Mar 2017  

    Accepted Date: 08 Mar 2017  

    Published Date: 09 Mar 2017

    Copyright © 2017 Jian-Hua G

    Citation:Jian-Hua G, Yu Z and Siya K. (2017). Terlipressin Abuse: An Occult Killer for Patients with Critical Condition. Mathews J Surgery. 1(2): 006.

     

    EDITORIAL

    Terlipressin is a vessel V2 receptor blocker, which has been the world widely used to better stop severe upper gastrointestinal tract bleeding, resulting from portal hypertension in cirrhosis. Nowadays Terlipressin is applied for other diseases including hepato-renal syndrome (Mattos et al., 2015), shock (Michel et al., 2016), ascites, and even with prevention of little-liver syndrome… etc., according to the most updated clinical guideline of Terlipressin. However, based on authors’ previous practice and evidence of the latest report of Šíma and colleagues study, it is more likely to lead to severe hyponatremia, and hypertension due to its adverse effects, which is difficult to control and then ultimately push patients with severe illness into potential risks of fatal consequence such as spontaneous cerebral hemorrhage or worsening of kidney failure or complexing the general conditions of patients during therapeutic course (Šíma et al., 2016)
    Now it is the time to remind physicians to focus on the pressing issue and to keep minds of raising their awareness of Terlipressin adverse effects.
    Sample tests amid the severe patients should be a groundwork at an uncertain time to improve surveillance risk of Terlipressin. Strict indication for Terlipressin and measures will be taken to pro legal interests of patients. The violator will be put on a blacklist that will be punished at regular, and the physicians’ participations will be limited in the future. Terlipressin doctors all tend to take for granted, but it really has to wise up to the fact that right drug in right time is crucial, helping to protect the patients from unexpected damage as well as life threatening. Finally, the root cause for misusing of Terlipressin is that physicians themselves who may chase gray income or are a lack of knowledge about Terlipressin. For example, if the patients with cirrhosis, which is ongoing hepatic bleeding and infectious shock, Terlipressin should be forbidden according to authors’ experience, otherwise, it may induce cerebral stroke mainly due to blood-clot dysfunction and hypertension. If the kidney failure is resulting from hypotension or infection but not a hepato-renal syndrome, Terlipressin is not suitable for use.
    In conclusion, Terlipressin should be strictly administered, to protect patients’ safety. Everyone should get to know the latest guidance of Terlipressin and its cautious notes of using it.

     

    Conflicts of Interest

    All authors declare that they have no conflicts of interests concerning the paper.

     

    REFERENCES

    1. Michel J, Hofbeck M, Spiller G, Renk H, et al. (2016). Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children. 19(1): 35-41.
    2. Michel J, Hofbeck M, Spiller G, Renk H, et al. (2017). Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children. 19(1): 35-41.
    3. Sima, M, Pokorny M, Padour F and Slanar O. (2016). Terlipressin Induced Severe Hyponatremia. Prague Med Rep. 117(1):68-72.

    © 2015 Mathews Open Access Journals. All Rights Reserved.

    Creative Commons License
    Open Access by Mathews Open Access Journals is licensed under a
    Creative Commons Attribution 4.0 International License.
    Based On a Work at Mathewsopenaccess.com